A case of bilateral acute depigmentation of the Iris in one of two identical twins

Abstract

Background: Bilateral Acute Depigmentation of the Iris (BADI) is a condition which was first described in a case series from Turkey by Tugal-Tutkin and Urgancioglu in (Graefes Arch Clin Exp Ophthalmol 244:742-6, 2006). The condition is characterized by bilateral acute depigmentation and discoloration of the iris stroma, pigment dispersion, and deposition of pigment in the angle. In our case we report a patient who developed BADI after receiving pitcher plant extract injections for chronic migraine, while her identical twin sister has normal iris architecture and pigmentation and never received any pitcher plant injections. Case presentation: Patient is a 41-year-old female with history of pitcher plant extract injections to her face for chronic migraine, who later developed bilateral depigmentation of the iris. She did not have any signs of anterior segment uveitis or iridocyclitis. She has an identical twin sister who maintained normal iris pigmentation during the entire course. Conclusions: Bilateral Acute depigmentation of the is a recently discovered condition described in the literature in Turkish patients (Tugal-Tutkun and Urgancioglu, Graefes Arch Clin Exp Ophthalmol 244: 742-6, 2006; Tugal-Tutkun et al., Ophthalmology 116(8):1552-7, 2009). This condition affects mainly young females and is characterized by acute bilateral stromal depigmentation, without other pathologic ocular findings. These patients usually maintain normal vision and do not develop significant glaucoma from pigment collecting in the anterior chamber angle. This condition can be mistaken for Fuchs' heterochromic iridocyclitis, pigment dispersion syndrome, pseudoexfoliation syndrome, and viral iridocyclitis. This is the first reported case in North America and is important for differentiation from the above pathologies. Our patient had a history of pitcher plant extract injections to the face but it is unclear if this is associated with our patient's development of BADI. As awareness of this condition progresses, a possible etiology may be elucidated.

Bilateral Acute Depigmentation of the Iris Following Refractive Surgery - An Untold Story

“…A class of "probable/likely" antibiotics is suggested by the body of research on the causation of fluoroquinolone antibiotics, particularly moxifloxacin [8]. Flulike syndrome, herpes virus infection, upper respiratory tract infections systemic antibiotics such as cefazolin, ampicillin/sulbactam, amoxicillin/clavulanate, trimethoprim/ sulfamethoxazole, cefixime, and moxifloxacin, fumigation therapy have been attributed as some of the etiological factors [5][6][7]. Other than topical Moxifloxacin instillation, none of the aforementioned pertinent histories applied to our patient.…”

Péczely Ignác öröksége: a colobomától a mesterséges intelligenciáig

“…A sötét pigmentált elváltozások mindig felhívják a szakemberek figyelmét, ugyanis az iris elváltozásainak 70%-át a melanocyták mennyiségének -többnyire UVexpozíció általi -növekedése okozza [15]. A pigmentáció mellett a depigmentáció is külön jelenség, melyet okozhat vírusfertőzés (például SARS-CoV-2, herpes simplex, varicella zoster, cytomegalovirus, ebolavírus) [18,21,22], de idiopathiásan is előfordul. Szerzett heterochromia iridist találunk Sturge-Weber-szindróma, Horner-szindróma, Fuchs-féle heterochromiás iridocyclitis, pigmentdiszperziós szindróma és Waardenburgszindróma esetén is [15,18,22].…”

“…A pigmentáció mellett a depigmentáció is külön jelenség, melyet okozhat vírusfertőzés (például SARS-CoV-2, herpes simplex, varicella zoster, cytomegalovirus, ebolavírus) [18,21,22], de idiopathiásan is előfordul. Szerzett heterochromia iridist találunk Sturge-Weber-szindróma, Horner-szindróma, Fuchs-féle heterochromiás iridocyclitis, pigmentdiszperziós szindróma és Waardenburgszindróma esetén is [15,18,22]. Tranziens heterochromiát sebészeti beavatkozások után is leírtak (például glaucoma-söntimplantációk, pars plana vitrectomia) [18,23], de irreverzibilis heterochromia a prosztaglan dinanalóg antiglaucomás terápia mellékhatásaként jelentkezik a leggyakrabban [18,23].…”